Summary of China Healthcare Trip Takeaways - Pharma Industry Overview - The report focuses on the **China Healthcare** sector, specifically discussing various pharmaceutical companies including **Hengrui**, **Hansoh**, **Huadong**, and **Henlius** [1] Key Company Insights Hengrui (1276.HK/600276.SS) - Participated in NRDL negotiations for **10 new drugs** and **5 new indications** in 2025, with outcomes meeting management expectations [2] - Management projects a **25%+ 3-year CAGR** for innovative drug sales, viewing this target as conservative compared to internal goals [2] - Anticipates accelerated growth in innovative drug sales post-NRDL inclusion, particularly for autoimmune drugs [2] - Plans slight growth in salesforce, reallocating resources to new areas like **cardio-metabolism** and **dermatology** [2] - Expects approval for **HRS-9531 (GLP-1/GIP injectable)** in 2026, with pricing strategy dependent on **tirzepatide's** NRDL entry [2][3] - Forecasts **Rmb2.1 billion** in licensing income for 9M25, with expectations for milestone payments from GSK and Kailera [3] Hansoh (3692.HK) - Secured NRDL renewal and indication expansion for **Ameile**, with peak sales projected at **~Rmb8 billion** by 2030 [4] - Upcoming approvals include **Ameile+chemo combo** in 1L NSCLC in 1Q26 and **GIP/GLP-1 injectable** in 2027 [5] - Highlighted the potential of **HS-20093 (B7H3 ADC)** in NSCLC, showing promising results in early trials [11] Huadong (000963.SZ) - Management expects **single-digit % revenue growth** and **~10% net profit growth** in 2025, with positive growth anticipated in 2026 [17] - Key approvals expected in 2026 include **CD19 CART** and **insulin degludec** [17] - Innovative drug sales projected to contribute **Rmb2.2 billion+** in 2025 [17][18] Henlius (2696.HK) - **HLX43 (PD-L1 ADC)** has enrolled over **400 subjects** globally, with data updates expected at **ASCO 2026** [12] - Discussing potential FDA approval pathways for HLX43, targeting a timeline of **2027-28** [12] - Plans to explore dosing by tumor type and expects **R&D costs** to remain above **Rmb1 billion** annually [13][14] Additional Insights - The overall sentiment in the **China Healthcare** industry is viewed as **attractive**, indicating positive growth prospects [8] - Companies are focusing on innovative drug development and strategic partnerships to enhance their market positions [3][12][14] Conclusion - The discussions during the China healthcare trip highlighted significant growth opportunities and strategic initiatives across the pharmaceutical sector, with a strong emphasis on innovative drug development and market expansion strategies.